Swing Therapeutics

Swing Therapeutics is a San Francisco-based digital health company founded in 2019, focusing on rheumatology and chronic illness management. Its core offering is Stanza, an FDA-cleared prescription digital therapeutic (PDT) for fibromyalgia, delivered via a smartphone app requiring 15 minutes of daily use. The company operates a hybrid model, offering both the Stanza therapy and the Swing Care clinic, and is backed by clinical data from randomized controlled trials demonstrating durable improvements in symptoms and quality of life. Swing is positioned in the growing digital therapeutics market, aiming to provide accessible, non-pharmacological options for chronic disease management.

Proprietary software platform for delivering prescription digital behavioral therapy (DBT) via smartphone, designed to be disease-specific, engaging, and requiring 15 minutes of daily use.

Direct competition in the FDA-cleared digital therapeutic space for fibromyalgia is currently limited, giving Swing a first-mover advantage. However, it faces indirect competition from traditional pharmaceuticals, other chronic pain apps (wellness/DTC), and telehealth services. Future competition is likely from other venture-backed digital therapeutic startups and potential entrants from large tech or pharma companies seeking to build or buy digital therapy portfolios.